Literature DB >> 29627909

Technological Advances in Stent Therapies: a Year in Review.

Jad Raffoul1, Ammar Nasir1,2, Andrew J P Klein3,4.   

Abstract

Stent technology has rapidly evolved since the first stainless steel bare metal stents with substantial developments in scaffolding, polymer, drug choice, drug delivery, and elution mechanisms. Most recently, there has been the evolution of bioabsorbable vascular scaffolds, potentially eliminating the need for long-term foreign object retention. These rapid developments have led to an ever-expanding selection of new stents, making the choice of which to use in which patient challenging. Operators must balance potential short- and long-term clinical ramifications, namely stent thrombosis, in-stent restenosis, target lesion revascularization, and target lesion failure. In this review, we hope to provide insight for interventional cardiologists on the details of stent technology and how this impacts outcomes, stent selection, and duration of dual-antiplatelet therapy duration post drug-eluting stent implantation.

Entities:  

Keywords:  Coronary artery disease; Dual-antiplatelet therapy; Stent therapy; Target lesion failure; Target lesion revascularization

Year:  2018        PMID: 29627909     DOI: 10.1007/s11936-018-0630-2

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  19 in total

1.  Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.

Authors:  Laura Mauri; Dean J Kereiakes; Robert W Yeh; Priscilla Driscoll-Shempp; Donald E Cutlip; P Gabriel Steg; Sharon-Lise T Normand; Eugene Braunwald; Stephen D Wiviott; David J Cohen; David R Holmes; Mitchell W Krucoff; James Hermiller; Harold L Dauerman; Daniel I Simon; David E Kandzari; Kirk N Garratt; David P Lee; Thomas K Pow; Peter Ver Lee; Michael J Rinaldi; Joseph M Massaro
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial).

Authors:  Pieter C Smits; Elvin Kedhi; Kees-Jan Royaards; Kaiyum Sheik Joesoef; Jochem Wassing; Tessa A M Rademaker-Havinga; Eugene McFadden
Journal:  J Am Coll Cardiol       Date:  2011-04-21       Impact factor: 24.094

3.  Duration of dual antiplatelet therapy after drug-eluting stents.

Authors:  Laura Mauri; Robert W Yeh; Dean J Kereiakes
Journal:  N Engl J Med       Date:  2015-04-02       Impact factor: 91.245

4.  Focused Update on Duration of Dual Antiplatelet Therapy for Patients With Coronary Artery Disease.

Authors:  Laura Mauri; Sidney C Smith
Journal:  JAMA Cardiol       Date:  2016-09-01       Impact factor: 14.676

5.  Real-life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).

Authors:  Giovanna Sarno; Bo Lagerqvist; Göran Olivecrona; Christoph Varenhorst; Mikael Danielewicz; Kristina Hambraeus; Daniel Lindholm; Truls Råmunddal; Nils Witt; Stefan James
Journal:  Catheter Cardiovasc Interv       Date:  2017-05-22       Impact factor: 2.692

6.  Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.

Authors:  Clemens von Birgelen; Marlies M Kok; Liefke C van der Heijden; Peter W Danse; Carl E Schotborgh; Martijn Scholte; R Melvyn Tjon Joe Gin; Samer Somi; K G van Houwelingen; M G Stoel; Frits H A F de Man; J Hans W Louwerenburg; Marc Hartmann; Paolo Zocca; Gerard C M Linssen; Job van der Palen; Carine J M Doggen; Marije M Löwik
Journal:  Lancet       Date:  2016-10-30       Impact factor: 79.321

7.  A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial.

Authors:  Gregg W Stone; Paul S Teirstein; Ian T Meredith; Bruno Farah; Christophe L Dubois; Robert L Feldman; Joseph Dens; Nobuhisa Hagiwara; Dominic J Allocco; Keith D Dawkins
Journal:  J Am Coll Cardiol       Date:  2011-04-04       Impact factor: 24.094

8.  Three-year safety and efficacy of treating all-comers with newer-generation Resolute Integrity or PROMUS Element stents in the randomised DUTCH PEERS (TWENTE II) trial.

Authors:  Liefke C van der Heijden; Marlies M Kok; Marije M Löwik; Peter W Danse; Gillian A J Jessurun; Raymond W M Hautvast; K Gert van Houwelingen; Martin G Stoel; Marc Hartmann; Gerard C Linssen; Carine J M Doggen; Clemens von Birgelen
Journal:  EuroIntervention       Date:  2017-04-20       Impact factor: 6.534

9.  Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial.

Authors:  Elvin Kedhi; Kaiyum Sheik Joesoef; Eugene McFadden; Jochem Wassing; Carlos van Mieghem; Dick Goedhart; Pieter Cornelis Smits
Journal:  Lancet       Date:  2010-01-07       Impact factor: 79.321

10.  Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial.

Authors:  Clemens von Birgelen; Hanim Sen; Ming Kai Lam; Peter W Danse; Gillian A J Jessurun; Raymond W M Hautvast; Gert K van Houwelingen; Alexander R Schramm; R Melvyn Tjon Joe Gin; Johannes W Louwerenburg; Frits H A F de Man; Martin G Stoel; Marije M Löwik; Gerard C M Linssen; Salah A M Saïd; Mark B Nienhuis; Patrick M J Verhorst; Mounir W Z Basalus; Carine J M Doggen; Kenneth Tandjung
Journal:  Lancet       Date:  2013-10-31       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.